It is an exciting time for those clinicians who manage patients with dyslipidemia. The field has medical therapies, novel and highly targeted mechanisms of action, new delivery methods, and safety and tolerability that suggest our therapeutic arsenal will be expanding soon and rapidly. At the AHA Scientific Sessions in New Orleans in November 2025, several very noteworthy trials were presented and warranted inclusion in the Late Breaker sessions a remarkable burst of new and exciting data. Our expert faculty Drs. Brown, Taub, and Toth were there on the scene and selected the trials that they felt were most impactful. In this continuing education webcast and podcast, they discuss these new data and provide contextualization for their potential clinical impact.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
11 of 11 courses listed here are free.
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Podcast / audio
- includes On-demand / recorded video
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedNov 26, 2025
-
Last day to claim creditNov 26, 2026 6 weeks left
-
AcademicCME, LLC Update on Clinical Data and Applications for Anti-CD20 Therapeutics to Treat Relapsing Multiple Sclerosis
-
AcademicCME, LLC 24-Hour Blood Pressure Burden: Aldosterone, Cardiorenal Risk, and the Next Generation of Blood Pressure Control
-
AcademicCME, LLC Beyond Factor Xa: FXI/XIa Inhibition and the Next Era of Stroke Prevention in Atrial Fibrillation
